The FDA on May 21, 2018 approved DOPTELETĀ® for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure. DOPTELETĀ® is a product of AkaRx Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement